LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Coagulation Analyzer Designed for Low-Volume Routine Testing

By LabMedica International staff writers
Posted on 07 Dec 2015
Print article
Image: The cobas t 411 coagulation analyzer for low-volume routine testing (Photo courtesy of Roche).
Image: The cobas t 411 coagulation analyzer for low-volume routine testing (Photo courtesy of Roche).
A new stand-alone, dedicated coagulation system suitable for low-volume routine testing (up to 120 samples per day) is now available.

The medical equipment manufacturer Roche (Basel, Switzerland) recently announced that its new lab-coagulation solution, the cobas t 411 analyzer, is now available for countries accepting the CE Marking for diagnostic tools.

The cobas t 411 analyzer was designed for use by low-volume central coagulation laboratories. Among its many innovative features, the instrument offers cap-piercing, which maximizes throughput when combined with five position rack-based sample handling. High on-board capacities for reagents and samples, along with continuous loading of reagents, samples, and consumables result in increased walk-away times. Efficient reagent use is optimized with on-board barcode scanning capability and cooled, tilted reagent racks. Patient safety is prioritized through the unique opto-mechanical detection principle by checking each sample before measurement, as well as the always available STAT port, whereby emergency samples can be immediately processed with test results returned in a timely fashion.

“We are entering into a new era of coagulation testing for Roche, through expansion of our coagulation solution and we will continue to develop systems which support our customer’s lab efficiency and productivity needs” said Jean-Claude Gottraux, head of professional diagnostics at Roche. “The cobas t 411 is the next foundation stone for Roche to become a total solution provider for coagulation testing in both the laboratory and at the point-of-care.”

Related Links:

Roche


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more